PACIRA PHARMACEUTICALS, INC. (NASDAQ:PCRX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On February28, 2019, Pacira Pharmaceuticals, Inc. issued a press release announcing its results for the fourth quarter and full-year ended December31, 2018.The full text of the press release issued in connection with the announcement is furnished as Exhibit99.1 to this Current Report on Form8-K.
The information in this Item 2.02 of Form8-K and Exhibit99.1 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 2.02. Financial Statements and Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Earnings Press Release dated February 28, 2019
|
Pacira Pharmaceuticals, Inc. Exhibit
EX-99.1 2 pcrx-123118×991.htm EXHIBIT 99.1 Exhibit NEWS RELEASEFOR IMMEDIATE RELEASEPacira Reports Record Fourth Quarter and Full Year Revenues– Increasing adoption of EXPAREL® Across Opioid-Sparing Pain Management Protocols —- EXPAREL net product sales expected to be in the range of $400M to $410M in 2019 —- Conference call today at 8:30 a.m. ET –PARSIPPANY,…
To view the full exhibit click here
About PACIRA PHARMACEUTICALS, INC. (NASDAQ:PCRX)
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company’s lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).